Tamtam Try Tamtam free
AstraZeneca logo

AstraZeneca account plan

Healthcare innovation through science

At a glance

AstraZeneca is a Cambridge, UK-based biopharmaceutical company with $58,739m of FY2025 Total Revenue and 96,100 employees.

AstraZeneca is a science-led biopharmaceutical company headquartered in Cambridge, UK, researching, developing, manufacturing and selling prescription medicines in Oncology, BioPharmaceuticals (CVRM, Respiratory & Immunology, Vaccines & Immune Therapies) and Rare Disease (Alexion). It has an active presence in more than 80 countries and sales in more than 125. FY2025 Total Revenue was $58,739m, up 9% (8% at CER), with Core Operating profit of $18,478m and Reported EPS of $6.60. It had 96,100 employees at end-2025. Its shares trade in London, Stockholm and, since 2 February 2026, directly on the NYSE; Pascal Soriot is CEO and Michel Demaré Chair.

Business units

Strategic priorities

Ambition 2030
Launch at least 20 new medicines and reach $80 billion Total Revenue by 2030; 11 NMEs had been approved by July 2026.
Transformative technologies
ADCs, bispecifics, cell therapy, T-cell engagers, radioconjugates and genomic medicines; 16 Phase III trials of next-generation bispecifics run across 8 tumour types.
Weight management and cardiovascular risk
Five Phase III trials started for the oral GLP-1 elecoglipron, alongside baxdrostat and the oral PCSK9 laroprovstat.
Enterprise AI
An Enterprise AI unit was created in December 2025; over 90% of the small-molecule discovery pipeline is AI-enabled, and a Tempus partnership builds a model to predict trial success.
US growth and localised supply
The US is projected at about 50% of Total Revenue by 2030, and manufacturing is being built in the US and China so the regions can operate independently.
Cost and systems efficiency
A post-Alexion restructuring with $4.0 billion expected cost targets about $2.2 billion of run-rate benefits by end-2026, and the Axial ERP project runs to 2030.

Latest results

In H1 2026 Total Revenue was $30,672m, up 9% (6% at CER), and Q2 Total Revenue was $15,384m. Core Operating profit rose 12% to $10,510m (Core Operating Margin 34%) and Core EPS 12% to $5.21. Oncology grew 18% to $14,124m and Rare Disease 13% to $4,911m, while BioPharmaceuticals fell 1% to $11,151m as Farxiga and Brilinta lost exclusivity. Net debt rose $3,538m to $26,912m. FY2026 guidance was reconfirmed at CER: Total Revenue up a mid-to-high single-digit percentage and Core EPS up a low double-digit percentage.

Investments and deals

$50 billion US programme
Planned investment in US manufacturing and R&D, including a $4.5 billion plant in Charlottesville, Virginia and a $2 billion Maryland expansion.
China and Singapore
$2.5 billion for a Beijing R&D centre and manufacturing, and a $1.5 billion ADC plant in Singapore.
Acquisitions and licences
EsoBiotec (up to $1 billion), SixPeaks Bio and FibroGen China in 2025; in 2026 Zegfrovy from Dizal ($600m upfront) and TQC3721 from CTTQ ($200m upfront), plus a $1,104m upfront payment to CSPC.
R&D and capex
$14.2bn invested in R&D in 2025; FY2026 capex is expected to rise by about a third from $3,270m.

Challenges and risks

Loss of exclusivity
Farxiga's US loss of exclusivity coincides with its Medicare negotiated price from 2026, and Brilinta and roxadustat are also declining; BioPharmaceuticals is described as being in a transitional period.
Pricing pressure
IRA price negotiation for Farxiga and Calquence, US most-favoured-nation pricing, European generic erosion and China volume-based procurement.
Pipeline setbacks
CARDIO-TTRansform (Wainua in ATTR-CM) and EMERALD-2 failed their primary endpoints in 2026.
Competition in China
China revenue was flat at $3,510m in H1 2026, with intense competition in EGFR TKIs and ADCs.
Geopolitics, tariffs and data
Principal risks include tariff and trade-control volatility, cybersecurity and data and AI governance.

What leadership says

“While we are disappointed by the CARDIO-TTRansform outcome, we are on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks.”

Pascal Soriot, CEO · H1 and Q2 2026 results report, 27 July 2026

“we don't need additional BD if we continue delivering as we expect to across the pipeline.”

Pascal Soriot, CEO · H1 and Q2 2026 results webinar, 27 July 2026

“Having AI tool is not sufficient. You have to have the data.”

Pascal Soriot, CEO · Positive Leadership podcast, 13 March 2026

“Our biopharmaceutical business is in a transitional period.”

Ruud Dobber, EVP BioPharmaceuticals Business Unit · H1 and Q2 2026 results webinar, 27 July 2026

Where a supplier can help

Plant construction and equipment
The $50 billion US programme, the Virginia and Maryland sites and the Singapore ADC plant, with capex up about a third in 2026, need engineering, equipment and automation suppliers.
Data for AI in R&D
The Enterprise AI unit and the CEO's point that AI needs data open room for data platforms, real-world data and AI infrastructure partners.
Clinical trial execution
25 key Phase III readouts over 18 months and more than 100 Phase III studies point to CRO, trial-site and patient-recruitment services.
ERP and efficiency programmes
The Axial ERP project to 2030 and the restructuring programme fit systems integration and process automation services.
Launch support
Launches such as Baxfendy and pre-launch work for tozorakimab create demand for commercial, market access and medical engagement services.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like AstraZeneca?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about AstraZeneca

What does AstraZeneca do?

AstraZeneca researches, develops, manufactures and sells prescription medicines in oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and rare diseases.

What is AstraZeneca's revenue?

FY2025 Total Revenue was $58,739m, up 9%; H1 2026 Total Revenue was $30,672m.

How many employees does AstraZeneca have?

AstraZeneca had 96,100 employees at the end of 2025.

Who leads AstraZeneca?

Pascal Soriot is CEO, Michel Demaré is Chair and Aradhana Sarin is CFO.

What is AstraZeneca's strategy?

Ambition 2030 targets at least 20 new medicines and $80 billion Total Revenue by 2030, driven by transformative technologies such as ADCs and bispecifics.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)